David R. Boulware

Infectious Disease

717 Delaware St Se
Suite 340
Minneapolis, MN 55414

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 404 publications

How have global guidelines advanced the management of cryptococcosis in two years?

How have global guidelines advanced the management of cryptococcosis in two years?

Journal: Expert review of anti-infective therapy

Published: August 11, 2026

Concordance Between Fingerprick and Venous Whole Blood CD4 Counts Using the Visitect CD4 Advanced disease platform.

Concordance Between Fingerprick and Venous Whole Blood CD4 Counts Using the Visitect CD4 Advanced disease platform.

Journal: The Journal of infectious diseases

Published: May 04, 2026

Closing the gap on antifungal resistance.

Closing the gap on antifungal resistance.

Journal: Nature medicine

Published: April 15, 2026

Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial.

Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: April 08, 2026

Once-Daily Dolutegravir-Based Antiretroviral Therapy Among Adults With Advanced HIV Disease Receiving 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis-Preventive Therapy and Fluconazole for Treatment of Cryptococcal Meningitis: Results of a Pharmacokinetic Study.

Once-Daily Dolutegravir-Based Antiretroviral Therapy Among Adults With Advanced HIV Disease Receiving 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis-Preventive Therapy and Fluconazole for Treatment of Cryptococcal Meningitis: Results of a Pharmacokinetic Study.

Journal: Open forum infectious diseases

Published: March 26, 2026

New 2030 Global Targets for Histoplasmosis from International Society for Human and Animal Mycology (ISHAM) 2025 Histoplasmosis Working Group.

New 2030 Global Targets for Histoplasmosis from International Society for Human and Animal Mycology (ISHAM) 2025 Histoplasmosis Working Group.

Journal: Emerging infectious diseases

Published: March 21, 2026

Change in plasma cryptococcal antigen titers in Uganda among outpatients with advanced HIV disease from 2017 to 2022 with rollout of national cryptococcal screening.

Change in plasma cryptococcal antigen titers in Uganda among outpatients with advanced HIV disease from 2017 to 2022 with rollout of national cryptococcal screening.

Journal: PloS one

Published: February 06, 2026

Central Nervous System Toxoplasmosis is an Under-Recognized Opportunistic infection in Uganda.

Central Nervous System Toxoplasmosis is an Under-Recognized Opportunistic infection in Uganda.

Journal: Journal of tropical medicine

Published: January 30, 2026

Use of DOOR and Win-Ratio Analysis in a Secondary Evaluation of a Histoplasmosis Clinical Trial.

Use of DOOR and Win-Ratio Analysis in a Secondary Evaluation of a Histoplasmosis Clinical Trial.

Journal: Open forum infectious diseases

Published: January 22, 2026

Is It Time to Use Single-Dose Amphotericin B for HIV-Related Cryptococcal Meningitis?

Is It Time to Use Single-Dose Amphotericin B for HIV-Related Cryptococcal Meningitis?

Journal: JAMA network open

Published: January 21, 2026

Lumbar puncture frequency and patient survival among persons hospitalized with cryptococcal meningitis in the United States.

Lumbar puncture frequency and patient survival among persons hospitalized with cryptococcal meningitis in the United States.

Journal: Medical mycology

Published: January 13, 2026

Pulmonary Aspergillosis Treated With Oral Amphotericin B (MAT2203) in a Patient With HIV-Related Cryptococcal Meningitis.

Pulmonary Aspergillosis Treated With Oral Amphotericin B (MAT2203) in a Patient With HIV-Related Cryptococcal Meningitis.

Journal: Clinical case reports

Published: January 10, 2026

Showing 1-12 of 404

Last Updated: 09/26/2026